CF Foundation Invests Up to $2M in Nanite Inc. to Conduct Early-Stage Research in Gene Delivery
We are investing up to $2 million in Nanite Inc. to explore a new way to deliver genetic therapies into the lung — delivery is one of the most significant challenges in creating a transformative treatment for all people with cystic fibrosis. Nanite will be developing a polymer nanoparticle, an exceptionally small synthetic molecule that can carry genetic therapies into the lung. Polymer nanoparticles are potentially safer and may be more versatile and stable than other delivery methods.
Last week, more than 175 advocates, including nearly 30 people with CF who participated virtually, and more than 4,500 community members from across the country, raised their collective voices and advocated for the CF community during the Foundation's 16th annual March on the Hill and Online Day of Action. Together, we met with more than 200 members of Congressional offices and sent more than 14,000 messages, helping to move the needle in support of the HELP Copays Act and the PASTEUR Act.
